Study of the toxicity of a new lipid complex formulation of amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 81-88

  Larabi, M ^a   Pages, N ^a,b   Pons, F ^b   Appel, M ^a   Gulik, A ^c   Schalatter, J ^d   Bouvet, S ^e   Barratt, Gillian ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CNRS   (France)

^d HÔPITAL JEAN VERDIER   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antifungal; Cytochrome P450; LD50; Lipid complex

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CYTOCHROME P450; ISOENZYME; LIVER ENZYME;

ACUTE TOXICITY; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG FORMULATION; FEMALE; HEMATOCRIT; HEMOLYSIS; IN VITRO STUDY; KIDNEY MASS; LD 50; LETHAL DOSE; LIVER FUNCTION; LIVER TOXICITY; LIVER WEIGHT; MEDICAL LITERATURE; MOUSE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PHAGOCYTE; TOXICITY TESTING;

EID: 0347287011     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh025     Document Type: Article

References (46)

1. Groll, A. H. & Walsh, T. J. (2002). Antifungal chemotherapy: advances and perspectives. Swiss Medical Weekly 132, 303-41.
2. Groll, A. H., Piscitelli, S. C. & Walsh, T. J. (1998). Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Advances in Pharmacology 44, 343-500.
3. Gallis, H. A., Drew, R. H. & Picard, W. W. (1990). Amphotericin B: 30 years of clinical experience. Review of Infectious Diseases 12, 308-29.
4. Bates, D. W., Su, L., Yu, D. T. et al. (2001). Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney International 60, 452-9.
5. Deray, G. (2002). Amphotericin B nephrotoxicity. Journal of Antimicrobial Chemotherapy 49, Suppl. 1, 37-41.
6. Walsh, T. J., Hiemenz, J. W., Seibel, N. L. et al. (1998). Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clinical Infectious Diseases 26, 1383-96.
7. Walsh, T. J., Seibl, N. L., Arndt, C. et al. (1999). Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatric Infectious Disease Journal 18, 702-8.
8. Wasan, K. M. & Lopez-Berestein, G. (1997). Diversity of lipid-based polyene formulations and their behaviour in biological systems. European Journal of Clinical Microbiology and Infectious Diseases 16, 81-92.
9. Christiansen, K. J., Bernard, E. M., Gold, J. W. M et al. (1985). Distribution and activity of amphotericin B in humans. Journal of Infectious Diseases 152, 1037-43.
10. Inselmann, G., Voss, V., Kunigk, F. et al. (1997). Influence of amphotericin B treatment duration on hepatic microsomal enzyme function in rats. Pharmacology 55, 87-94.
11. Inselmann, G., Volkmann, A. & Heidemann, H. (2000). Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and cytochrome P450 in rats. Antimicrobial Agents and Chemotherapy 44, 131-3.
12. Gaeta, G. B., Utili, R., Adilnolfi, L. E. et al. (1989). Effects of amphotericin B on the excretory function and the colloid clearance capacity of the perfused rat liver. Journal of Hepatology 8, 344-50.
13. Heidemann, H., Holzlohner, U., Heidemann, J. et al. (1992). Effect of amphotericin B on hepatic cytochrome P-450 and glucose-6-phosphatase in the rat. Journal of Hepatology 14, 300-4.
14. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 512-31.
15. Hartsel, S. & Bolard, J. (1996). Amphotericin B: new life for an old drug. Trends in Pharmacological Sciences 17, 445-9.
16. Janoff, A. S., Boni, L. T., Popescu, M. C. et al. (1988). Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proceedings of the National Academy of Sciences, USA 85, 6122-6.
17. Walsh, T. J., Whitcomb, P., Piscitelli, S. et al. (1997). Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrobial Agents and Chemotherapy 41, 1944-8.
18. Wingard, J. R., White, M. H., Anaissie, E. et al. and L Amph/ABLC Collaborative Study Group. (2000). A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin 6 lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clinical Infectious Diseases 31, 1155-63.
19. Olsen, S. J., Swerdel, M. R., Blue, B. et al. (1991). Tissue distribution of AmB lipid complex in laboratory animals. Journal of Pharmacy and Pharmacology 43, 831-5.
20. Rapp, R. P., Gubbins, P. O. & Evans, M. E. (1997). Amphotericin B lipid complex. Annals of Pharmacotherapy 31, 1174-86.
21. Wasan, K. M., Kennedy, A. L., Cassidy, S. M. et al. (1998). Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrobial Agents and Chemotherapy 42, 3146-52.
22. Cannon, P., Garey, K. W. & Danziger, L. H. (2001). A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2, 1107-14.
23. Ramaswamy, M., Peteherych, K. D., Kennedy, A. L. et al. (2001). Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrobial Agents and Chemotherapy 45, 1184-91.
24. Slain, D., Miller, K., Khakoo, R. et al. (2002). Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study. Clinical Therapeutics 24, 1636-42.
25. Barenholz, Y. & Cohen, R. (1995). Rational design of amphiphile-based drug carriers and sterically stabilized carriers. Journal of Liposome Research 5, 905-32.
26. Adedoyin, A., Bernardo, J. F., Swenson, C. E. et al. (1997). Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrobial Agents and Chemotherapy 41, 2201-8.
27. Larabi, M., Legrand, P., Appel, M. et al. (2001). Reduction of NO synthase expression and TNF alpha production of macrophages by amphotericin B lipid carriers. Antimicrobial Agents and Chemotherapy 45, 553-62.
28. Litchfield, J. T. & Wilcoxon, F. (1949). A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96, 99-113.
29. Omura, T. & Sato, R. (1964). The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry 239, 2370-8.
30. Lasic, D. D. & Papahadjopoulos, D. (1998). Medical Applications of Liposomes. Elsevier, Amsterdam, The Netherlands.
31. Brajtburg, J., Powderly, W. G., Kobayashi, G. S. et al. (1990). Amphotericin B: current understanding of mechanisms of action. Antimicrobial Agents and Chemotherapy 34, 183-8.
32. Barwicz, J., Gruda, I. & Tancrede, P. (2000). A kinetic study of the oxidation effects of amphotericin B on human low-density lipoproteins. FEBS Letters 465, 83-6.
33. Larabi, M., Yardley, V., Bories, C. et al. (2000). Original lipid formulation of amphotericin B: biological evaluation. In Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials, Paris, France, 2000. Abstract 0214, Oral Communication, pp. 35-6. Controlled Release Society, Deerfield, IL, USA.
34. Groll, A. H., Mickiene, D., Piscitelli, S. C. et al. (2000). Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrobial Agents and Chemotherapy 44, 408-10.
35. Lin, A. C., Goldwasser, E., Bernard, E. M. et al. (1990). Amphotericin B blunts erythropoietin response to anaemia. Journal of Infectious Diseases 161, 348-51.
36. Harbarth, S., Pestotnik, S. L., Lloyd, J. F. et al. (2001). The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. American Journal of Medicine 111, 528-34.
37. Heidemann, H. T., Brune, K. H., Sabra, R. et al. (1992). Acute and chronic effects of flucytosine on amphotericin B nephrotoxicity in rats. Antimicrobial Agents and Chemotherapy 36, 2670-5.
38. Proffitt, R. T., Satorius, A., Chiang, S. M. et al. (1991). Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 49-61.
39. Lee, J. W., Amantea, M. A., Francis, P. A. et al. (1994). Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrobial Agents and Chemotherapy 38, 713-8.
40. Fielding, R. M., Singer, A. W., Wang, L. H. et al. (1992). Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents and Chemotherapy 36, 299-307.
41. Boswell, G. W., Bekersky, I., Buell, D. et al. (1998). Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrobial Agents and Chemotherapy 42, 263-8.
42. Walsh, T. J., Whitcomb, P., Piscitelli, S. et al. (1997). Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrobial Agents and Chemotherapy 41, 1944-8.
43. Walsh, T. J., Yeldandi, V., McEvoy, M. et al. (1998). Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrobial Agents and Chemotherapy 42, 2391-8.
44. Nelson, D. R. (1999). Cytochrome P450 and the individuality of species. Archives of Biochemistty and Biophysics 369, 1-10.
45. Rex, J. H., Pappas, P. G., Karchmer, A. W. et al. and National Institute of Allergy and Infectious Diseases Mycoses Study Group. (2003). A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clinical Infectious Diseases 36, 1221-8.
46. Thummel, K. E. & Wilkinson, G. R. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 38, 389-430.